HCW Biologics Inc
Company Profile
Business description
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
Contact
2929 N Commerce Parkway
MiramarFL33025
USAT: +1 954 842-2024
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
36
Stocks News & Analysis
stocks
Bapcor earnings: Under review amid sharply lower profits and a massively dilutive equity raise
stocks
Earnings winners: WOW, WTC and FMG set the tone
stocks
Do dividends build or limit wealth creation?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,413.00 | 4.30 | 0.05% |
| CAC 40 | 8,620.93 | 61.86 | 0.72% |
| DAX 40 | 25,289.02 | 113.08 | 0.45% |
| Dow JONES (US) | 49,499.20 | 17.05 | 0.03% |
| FTSE 100 | 10,846.70 | 40.29 | 0.37% |
| HKSE | 26,497.26 | 116.24 | 0.44% |
| NASDAQ | 22,878.38 | 273.69 | -1.18% |
| Nikkei 225 | 58,274.87 | 478.52 | -0.81% |
| NZX 50 Index | 13,678.65 | 7.94 | 0.06% |
| S&P 500 | 6,908.86 | 37.27 | -0.54% |
| S&P/ASX 200 | 9,177.10 | 1.80 | 0.02% |
| SSE Composite Index | 4,139.09 | 7.54 | -0.18% |